Study or Subgroup	Rhythm control Events	Rhythm control Total	Rate control Events	Rate control Total	Weight	Risk Ratio M-H, Random, 95% CI
4.4.1 Amiodarone with or without electrical cardioversion						
CAFÉ-II 2009	1	30	1	31	0.1%	1.03 [0.07, 15.78]
CRRAFT 2004	3	45	6	40	0.5%	0.44 [0.12, 1.66]
Gillinov 2016	56	261	60	262	6.8%	0.94 [0.68, 1.29]
Hu 2005	4	92	10	91	0.6%	0.40 [0.13, 1.22]
PIAF 2000	29	122	30	124	3.8%	0.98 [0.63, 1.53]
Subtotal (95% CI)		**550**		**548**	**11.7%**	**0.89 [0.69, 1.14]**
Total events	93		107			
Heterogeneity: Tau² = 0.00; Chi² = 3.39, df = 4 (P = 0.49); I² = 0%						
Test for overall effect: Z = 0.93 (P = 0.35)						
4.4.2 Mixed (as according to the treating physician)						
Brignole 1997	1	19	0	21	0.1%	3.30 [0.14, 76.46]
J-RHYTHM 2009	18	419	22	404	2.1%	0.79 [0.43, 1.45]
Lee 2000	2	27	0	23	0.1%	4.29 [0.22, 84.97]
Marshall 1999	2	21	2	37	0.2%	1.76 [0.27, 11.61]
PAF 2 2002	15	68	7	69	1.1%	2.17 [0.95, 5.00]
Subtotal (95% CI)		**554**		**554**	**3.7%**	**1.36 [0.74, 2.51]**
Total events	38		31			
Heterogeneity: Tau² = 0.10; Chi² = 5.04, df = 4 (P = 0.28); I² = 21%						
Test for overall effect: Z = 0.98 (P = 0.33)						
4.4.3 Catheter ablation						
CAMTAF 2014	2	26	2	24	0.2%	0.92 [0.14, 6.05]
Jones 2013	4	26	0	26	0.1%	9.00 [0.51, 159.15]
MacDonald 2011	5	22	0	18	0.1%	9.09 [0.54, 154.07]
PABA-CHF 2008	2	41	5	40	0.3%	0.39 [0.08, 1.90]
Subtotal (95% CI)		**115**		**108**	**0.8%**	**1.65 [0.34, 8.07]**
Total events	13		7			
Heterogeneity: Tau² = 1.33; Chi² = 6.27, df = 3 (P = 0.10); I² = 52%						
Test for overall effect: Z = 0.62 (P = 0.53)						
4.4.4 Electrical cardioversion with antiarrhythmic drug therapy following sinus rhythm restoration						
HOT CAFE 2004	13	104	5	101	0.8%	2.52 [0.93, 6.83]
RACE 2002	60	266	44	256	5.8%	1.31 [0.93, 1.86]
STAF 2003	9	100	10	100	1.1%	0.90 [0.38, 2.12]
Subtotal (95% CI)		**470**		**457**	**7.7%**	**1.34 [0.91, 1.98]**
Total events	82		59			
Heterogeneity: Tau² = 0.03; Chi² = 2.41, df = 2 (P = 0.30); I² = 17%						
Test for overall effect: Z = 1.48 (P = 0.14)						
4.4.5 Ibutilide						
PIPAF 2003a	0	10	0	6		Not estimable
Subtotal (95% CI)		**10**		**6**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
4.4.6 Propafenone						
PIPAF 2003	0	20	1	6	0.1%	0.11 [0.01, 2.43]
Subtotal (95% CI)		**20**		**6**	**0.1%**	**0.11 [0.01, 2.43]**
Total events	0		1			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.40 (P = 0.16)						
4.4.7 Antiarrhythmic therapy with or without electrical cardioversion						
AF-CHF 2008	436	647	409	650	34.3%	1.07 [0.99, 1.16]
AFFIRM 2002	1374	2033	1220	2027	41.6%	1.12 [1.07, 1.18]
Subtotal (95% CI)		**2680**		**2677**	**75.9%**	**1.11 [1.07, 1.16]**
Total events	1810		1629			
Heterogeneity: Tau² = 0.00; Chi² = 1.01, df = 1 (P = 0.31); I² = 1%						
Test for overall effect: Z = 5.01 (P < 0.00001)						
4.4.10 Total endoscopic ablation						
Fengsrud 2016	1	15	0	19	0.1%	3.75 [0.16, 85.98]
Subtotal (95% CI)		**15**		**19**	**0.1%**	**3.75 [0.16, 85.98]**
Total events	1		0			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.83 (P = 0.41)						
Total (95% CI)		**4414**		**4375**	**100.0%**	**1.09 [1.00, 1.19]**
Total events	2037		1834			
Heterogeneity: Tau² = 0.00; Chi² = 24.98, df = 20 (P = 0.20); I² = 20%						
Test for overall effect: Z = 1.89 (P = 0.06)						
Test for subgroup differences: Chi² = 7.35, df = 6 (P = 0.29), I² = 18.4%